Lichenoid drug eruption caused by imatinib mesylate in a Chinese patient with gastrointestinal stromal tumor

Imatinib mesylate, the first agent approved for the treatment of unresectable or metastatic gastrointestinal stromal tumor, is a tyrosine kinase inhibitor targeting (KIT) and the platelet-derived growth factor receptor-α and -β. However, imatinib administration can be accompanied by various adverse...

Ausführliche Beschreibung